Shire

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

Baxalta Incorporated is a biopharmaceutical company specializing in the development of therapies aimed at addressing various medical needs, particularly in the areas of hemophilia, immunology, and oncology. The company offers a range of biopharmaceutical products for the treatment of bleeding disorders, immune deficiencies, and chronic conditions, with its therapies available in over 100 countries. Baxalta operates biological manufacturing across 12 facilities, focusing on recombinant production and plasma fractionation. Through its commitment to innovation and excellence, Baxalta strives to improve patient outcomes by providing differentiated therapies that meet specific health challenges.

Dyax Corp. is a biopharmaceutical company that specializes in the development and commercialization of treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated disorders. Its primary product, KALBITOR (ecallantide), is approved for the treatment of acute HAE attacks in patients aged 16 and older and is distributed through various wholesale, hospital, and specialty pharmacy channels in the United States. Dyax is also developing DX-2930, a human monoclonal antibody designed to provide prophylactic treatment for HAE, which is currently in Phase 1b clinical trials. The company has formed partnerships with various organizations to expand the reach of KALBITOR and other treatments in multiple regions, including agreements with CVie Therapeutics and Novellus Biopharma AG for commercialization in Asia and Latin America, respectively. Additionally, collaborations with CMIC Co., Ltd. and Sigma-Tau Rare Diseases S.A. aim to develop subcutaneous ecallantide for HAE treatment in Japan and other territories worldwide. Founded in 1989, Dyax Corp. is headquartered in Burlington, Massachusetts, and operates as a subsidiary of Shire Pharmaceuticals International.

Foresight Biotherapeutics is a clinical-stage drug development company focused on creating innovative therapies to meet significant unmet needs in the fields of ophthalmology and otolaryngology. The company's Povidone-Iodine (PVP-I) technology is a key advancement in treating ocular and otic inflammation caused by bacterial, viral, and fungal infections. This platform utilizes PVP-I, a well-established broad-spectrum antiseptic that has no known microbial resistance, and combines it with various anti-inflammatory agents to enhance treatment efficacy. Through its research and development efforts, Foresight Biotherapeutics aims to provide effective solutions for patients suffering from these conditions.

Meritage Pharma, Inc. is a company focused on developing prescription products for gastrointestinal and atopic diseases. Founded in 2008 and based in San Diego, California, it specializes in budesonide, a glucocorticoid steroid used in treatments for conditions such as pediatric asthma, allergic rhinitis, and Crohn's disease. The company's primary product candidate is an oral budesonide suspension aimed at treating adolescents and young adults with eosinophilic esophagitis, an allergic inflammation affecting the gastrointestinal tract. Through its innovative approaches, Meritage Pharma seeks to address significant medical needs in these areas.

NPS Pharmaceuticals is a biopharmaceutical company based in Bedminster, New Jersey, dedicated to developing therapeutic products for gastrointestinal and endocrine disorders, particularly focusing on rare diseases. The company offers Gattex and Revestive for the treatment of short bowel syndrome (SBS) in adults, as well as a pediatric formulation of Gattex/Revestive that is undergoing clinical trials. Additionally, NPS Pharmaceuticals is developing Natpara, a bioengineered parathyroid hormone replacement therapy for hypoparathyroidism, which currently lacks approved treatment options. The company is also advancing NPSP795, a calcilytic agent in clinical development for autosomal dominant hypocalcemia, an ultra-rare genetic disorder. NPS Pharmaceuticals collaborates with several major pharmaceutical companies and has numerous royalty-based products in its portfolio, addressing conditions such as hyperparathyroidism and pain management. With a commitment to innovation and patient-centric solutions, NPS Pharmaceuticals aims to transform the lives of patients facing significant unmet medical needs in the rare disease space.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Lumena Pharmaceuticals is focused on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target intestinal transporters, minimizing systemic toxicity and absorption in the body. Their lead candidate, LUM001, has undergone extensive evaluation through 12 clinical studies involving over 1,400 subjects, positioning it for rapid advancement in treating cholestatic liver disease in both pediatric and adult patients. In addition to its primary goal of addressing rare liver diseases, Lumena's innovative therapeutic approach shows promise for treating metabolic liver diseases, a significant and rising health concern affecting both children and adults.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Fibrotech Therapeutics focuses on developing innovative drug candidates aimed at treating fibrosis related to various chronic conditions. The company's research and development efforts are directed towards addressing diseases such as diabetic nephropathy, kidney diseases, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006 and based in Wonga Park, Australia, Fibrotech Therapeutics is dedicated to improving patient outcomes through its targeted therapeutic solutions.

Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.

ViroPharma Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, particularly those that require specialized medical attention in hospital settings. The company has two marketed products, including Vancocin HCl capsules, an oral formulation of vancomycin hydrochloride approved by the U.S. Food and Drug Administration. Vancocin is utilized for treating antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infections and enterocolitis linked to Staphylococcus aureus, including resistant strains. In addition to its marketed products, ViroPharma also has three ongoing development programs targeting various diseases, including cytomegalovirus and picornavirus infections.

Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco that focuses on developing a novel class of small molecule antagonists targeting lymphocyte function-associated antigen-1 (LFA-1). These antagonists are being developed as topical agents aimed at addressing significant unmet medical needs in the fields of ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative treatments that can improve patient outcomes in these areas.

Premacure develops and commercializes insulin-like growth factor I (IGF-I) for unmet medical needs for the neonate. It develops IGF-I together with or without its IGFBP-3 natural binding protein for the prevention of complications of preterm birth.

ArmaGen, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapies for severe neurological diseases, particularly lysosomal storage disorders. The company's product pipeline includes AGT-182, aimed at treating Hunter syndrome, and AGT-181, designed for Hurler syndrome. ArmaGen's innovative therapies are engineered to penetrate the blood-brain barrier, addressing neurological complications associated with various conditions, including neurodegenerative diseases like Alzheimer’s and Parkinson’s. Founded in 2001, ArmaGen aims to enhance treatment options for patients suffering from these challenging disorders.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic and inflammatory diseases. The company’s primary targets include conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's drug portfolio features PRM-151, a recombinant form of human pentaxin-2 protein, and PRM-167, a variant designed for intravitreal delivery. These therapeutics are aimed at regulating monocyte-derived cell populations, which are critical in fibrotic, inflammatory, and autoimmune diseases. By specifically addressing these cells at injury sites, Promedior seeks to promote tissue healing and minimize systemic side effects commonly associated with existing therapies. The company was incorporated in 2006 and was previously known as Fibrotix, Inc.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.

Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft®, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with research & development offices in New York, NY and manufacturing operations in La Jolla, CA.

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Proclara Biosciences, Inc. is a biotechnology company focused on developing therapies for chronic neurodegenerative diseases and conditions associated with protein misfolding, such as Alzheimer’s and Parkinson’s diseases, as well as various orphan indications. Founded in 2006 and headquartered in Cambridge, Massachusetts, the company utilizes a protein disaggregation platform to create disease-modifying drug candidates. One of its notable candidates, NPT001, aims to disaggregate existing amyloid plaques associated with Alzheimer’s in preclinical models. Proclara's approach targets multiple misfolded proteins, positioning the company to potentially transform treatment outcomes for patients suffering from these challenging diseases.

Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. The company addresses a range of conditions, including severe chronic constipation, ascites, and pediatric reflux, as well as severe GI motility disorders like refractory gastro-oesophageal reflux disease. Its lead product, Resolor, is specifically designed for the symptomatic treatment of chronic constipation in women, with ongoing research for its efficacy in males and children, as well as in cases of opioid-induced constipation and post-operative ileus. Movetis is also developing M0002, currently in Phase II trials for treating ascites, and M0003, which is set to enter Phase II development for symptomatic relief of heartburn and regurgitation in patients unresponsive to proton pump inhibitors. Additionally, the company has two prioritized compounds from its preclinical portfolio and maintains partnerships with universities in Ghent, Leuven, and Rotterdam. Founded in 2006, Movetis is based in Turnhout, Belgium.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

New River Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing novel medications that represent generational improvements over widely-prescribed drugs in expansive markets. The company employs its proprietary Carrierwave™ technology to create new molecular entities derived from public domain actives. Its product pipeline includes an amphetamine derivative and an opioid derivative designed to serve as effective alternatives to existing opioid medications, thereby providing patients with improved options for managing acute pain. Through its innovative approach, New River Pharmaceuticals aims to address significant healthcare needs in the pharmaceutical sector.

BIKAM Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. BIKAM's research centers on small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins within the retina. Their lead product is an orally active pharmacological chaperone that targets misfolded rod opsin, which is implicated in retinitis pigmentosa, helping to correct its trafficking to the rod cell surface and outer segment. Through its innovative approach, BIKAM Pharmaceuticals strives to provide new treatment options for patients suffering from these serious retinal conditions.